Johnson & Johnson (NYSE:JNJ) has confirmed its acquisition of Shockwave Medical (NASDAQ:SWAV) for a $13.1 billion. For every Shockwave share, Johnson & Johnson will pay $335. The agreement received unanimous approval from the boards of both firms.
According to a press statement from the company, this acquisition is expected to enhance the operating margins of Johnson & Johnson and its MedTech division immediately. Nonetheless, financing expenses will marginally decrease the adjusted earnings per share by approximately $0.10 in 2024 and $0.17 in 2025.
The acquisition of Shockwave, with its pioneering Intravascular Lithotripsy (IVL) technology, offers a unique opportunity to expand Johnson & Johnson’s influence in cardiovascular interventions and deliver increased value to patients, shareholders, and healthcare systems worldwide. Shockwave specializes in developing a device that utilizes shockwaves to break apart calcified plaque in the arteries of the heart, a method akin to the treatment of kidney stones.